# Extracted Content from https://ndc.services.cdc.gov/case-definitions/babesiosis-2011/

Babesiosis ( Babesia spp.) 2011 Case Definition | CDC  
Skip directly to site content  
Skip directly to search  
An official website of the United States government  
Here's how you know  
Official websites use .gov  
A .gov website belongs to an official government organization in the United States.  
Secure .gov websites use HTTPS  
A  
lock  
(  
) or  
https://  
means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.  
National Notifiable Diseases Surveillance System (NNDSS)  
Explore Topics  
Search  
Search  
Clear Input  
For Everyone  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View all  
Related Topics:  
NDC Application  
View All  
search  
close search  
search  
National Notifiable Diseases Surveillance System (NNDSS)  
Menu  
Close  
search  
For Everyone  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
Related Topics  
NDC Application  
View All  
National Notifiable Diseases Surveillance System (NNDSS)  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
April 16, 2021  
Case Definitions  
Message Mapping Guides  
Supporting Documents for Implementation  
Event Codes & Other Surveillance Resources  
Babesiosis (  
Babesia  
spp.)  
2011 Case Definition  
Babesiosis (  
Babesia  
spp.)  
2011 Case Definition  
NOTE:  
A surveillance case definition is a set of uniform criteria used to define a disease for public health surveillance. Surveillance case definitions enable public health officials to classify and count cases consistently across reporting jurisdictions. Surveillance case definitions are not intended to be used by healthcare providers for making a clinical diagnosis or determining how to meet an individual patient’s health needs.  
CSTE Position Statement(s)  
10-ID-27  
Clinical Description  
Babesiosis is a parasitic disease caused by intraerythrocytic protozoa of the  
Babesia  
genus (  
Babesia microti  
and other species).  
Babesia  
are transmitted in nature through the bites of infected ticks but can also be acquired through contaminated blood components from asymptomatic parasitemic donors or, more rarely, transplacentally.  
Babesia  
infection can range from subclinical to life-threatening. Clinical manifestations, if any, can include hemolytic anemia and nonspecific influenza-like signs and symptoms (e.g., fever, chills, sweats, headache, myalgia, arthralgia, malaise, fatigue, generalized weakness). Splenomegaly, hepatomegaly, or jaundice may be evident. In addition to signs of hemolytic anemia, laboratory findings may include thrombocytopenia, proteinuria, hemoglobinuria, and elevated levels of liver enzymes, blood urea nitrogen, and creatinine. Risk factors for severe babesiosis include asplenia, advanced age, and other causes of impaired immune function (e.g., HIV, malignancy, corticosteroid therapy). Some immunosuppressive therapies or conditions may mask or modulate the clinical manifestations (e.g., the patient may be afebrile). Severe cases can be associated with marked thrombocytopenia, disseminated intravascular coagulation, hemodynamic instability, acute respiratory distress, myocardial infarction, renal failure, hepatic compromise, altered mental status, and death.  
Clinical Criteria  
For the purposes of surveillance:  
Objective: one or more of the following: fever, anemia, or thrombocytopenia.  
Subjective: one or more of the following: chills, sweats, headache, myalgia, or arthralgia.  
Laboratory Criteria For Diagnosis  
For the purposes of surveillance:  
Laboratory confirmatory:  
Identification of intraerythrocytic  
Babesia  
organisms by light microscopy in a Giemsa, Wright, or Wright-Giemsa–stained blood smear;  
OR  
Detection of  
Babesia microti  
DNA in a whole blood specimen by polymerase chain reaction (PCR);  
OR  
Detection of  
Babesia  
spp. genomic sequences in a whole blood specimen by nucleic acid amplification;  
OR  
Isolation of  
Babesia  
organisms from a whole blood specimen by animal inoculation.  
Laboratory supportive:  
Demonstration of a  
Babesia microti  
Indirect Fluorescent Antibody (IFA) total immunoglobulin (Ig) or IgG antibody titer of greater than or equal to (≥) 1:256 (or ≥1:64 in epidemiologically linked blood donors or recipients);  
OR  
Demonstration of a  
Babesia microti  
Immunoblot IgG positive result;  
OR  
Demonstration of a  
Babesia divergens  
IFA total Ig or IgG antibody titer of greater than or equal to (≥) 1:256;  
OR  
Demonstration of a  
Babesia duncani  
IFA total Ig or IgG antibody titer of greater than or equal to (≥) 1:512.  
Epidemiologic Linkage  
Epidemiologic evidence for transfusion transmission.  
For the purposes of surveillance, epidemiologic linkage between a transfusion recipient and a blood donor is demonstrated if all of the following criteria are met:  
In the transfusion recipient:  
Received one or more red blood cell (RBC) or platelet transfusions within one year before the collection date of a specimen with laboratory evidence of  
Babesia  
infection; AND  
At least one of these transfused blood components was donated by the donor described below; AND  
Transfusion-associated infection is considered at least as plausible as tickborne transmission; AND  
In the blood donor:  
Donated at least one of the RBC or platelet components that was transfused into the above recipient; AND  
The plausibility that this blood component was the source of infection in the recipient is considered equal to or greater than that of blood from other involved donors. (More than one plausible donor may be linked to the same recipient.)  
Case Classification  
Suspected  
A case that has confirmatory or supportive laboratory results, but insufficient clinical or epidemiologic information is available for case classification (e.g., only a laboratory report was provided).  
Probable  
a case that has supportive laboratory results and meets at least one of the objective clinical evidence criteria (subjective criteria alone are not sufficient);  
OR  
a case that is in a blood donor or recipient epidemiologically linked to a confirmed or probable babesiosis case (as defined above)  
AND  
:  
has confirmatory laboratory evidence but does not meet any objective or subjective clinical evidence criteria;  
OR  
has supportive laboratory evidence and may or may not meet any subjective clinical evidence criteria but does not meet any objective clinical evidence criteria.  
Confirmed  
A case that has confirmatory laboratory results and meets at least one of the objective or subjective clinical evidence criteria, regardless of the mode of transmission (can include clinically manifest cases in transfusion recipients or blood donors).  
Comments  
The validity of the diagnosis of babesiosis is highly dependent on the laboratory that performs the testing. For example, differentiation between Plasmodium and  
Babesia  
organisms on peripheral blood smears can be difficult. Confirmation of the diagnosis of babesiosis by a reference laboratory is strongly encouraged, especially for patients without residence in or travel to areas known to be endemic for babesiosis.  
A positive  
Babesia  
IFA result for immunoglobulin M (IgM) is insufficient for diagnosis and case classification of babesiosis in the absence of a positive IFA result for IgG (or total Ig). If the IgM result is positive but the IgG result is negative, a follow-up blood specimen drawn at least one week after the first should be tested. If the IgG result remains negative in the second specimen, the IgM result likely was a false positive.  
When interpreting IFA IgG or total Ig results, it is helpful to consider factors that may influence the relative magnitude of  
Babesia  
titers (e.g., timing of specimen collection relative to exposure or illness onset, the patient’s immune status, the presence of clinically manifest versus asymptomatic infection). In immunocompetent persons, active or recent  
Babesia  
infections that are symptomatic are generally associated with relatively high titers (although antibody levels may be below the detection threshold early in the course of infection); titers can then persist at lower levels for more than a year. In persons who are immunosuppressed or who have asymptomatic  
Babesia  
infections, active infections can be associated with lower titers.  
Babesia microti  
is the most frequently identified agent of human babesiosis in the United States; most reported tick-borne cases have been acquired in parts of northeastern and north-central regions. Sporadic U.S. cases caused by other  
Babesia  
agents include  
B. duncani  
(formerly the WA1 parasite) and related organisms (CA1-type parasites) in several western states as well as parasites characterized as "  
B. divergens  
like" (MO1 and others) in various states. Serologic and molecular tests available for  
B. microti  
infection do not typically detect these other  
Babesia  
agents.  
Blood-borne transmission of  
Babesia  
is not restricted by geographic region or season. The epidemiologic linkage criteria for transfusion transmission that are described here provide a low threshold for asymptomatic donor or recipient cases to be considered probable cases for surveillance purposes and are not intended to be regulatory criteria. Transfusion investigations entail laboratory testing for evidence of  
Babesia  
infection in recipients and donors as well as epidemiologic assessments of the plausibilities of blood- and tick-borne transmission.  
Related Case Definition(s)  
Babesiosis | 2025 Case Definition  
Back to Top  
Sources  
Print  
Share  
Facebook  
LinkedIn  
Twitter  
Syndicate  
Content Source:  
Case Definitions  
Message Mapping Guides  
Supporting Documents for Implementation  
Event Codes & Other Surveillance Resources  
National Notifiable Diseases Surveillance System (NNDSS)  
NNDSS receives and shares case data from state, local, and territorial health departments to help public health monitor, control, and prevent serious diseases.  
View All  
About About National Notifiable Diseases Surveillance System  
What is Case Surveillance?  
Case Surveillance Modernization  
Infectious Disease Tables  
Non-Infectious Disease Data  
Technical Resource Center  
Case Surveillance in Action  
Contact Us  
View All  
Sign up for Email Updates  
Contact CDC  
Organization  
Policies  
Web Policies  
Languages  
Languages  
Español  
Language Assistance  
Archive  
CDC Archive  
Public Health Publications  
Contact Us  
About CDC  
Organization  
Policies  
Web Policies  
Languages  
Languages  
Español  
Language Assistance  
Archive  
CDC Archive  
Public Health Publications  
HHS.gov  
USA.gov